<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828970</url>
  </required_header>
  <id_info>
    <org_study_id>09/43</org_study_id>
    <nct_id>NCT01828970</nct_id>
  </id_info>
  <brief_title>Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients</brief_title>
  <acronym>GlyCEDIA</acronym>
  <official_title>Glycemic Control Assessed by Continuous Glucose Monitoring in Hemodialyzed Patients With Diabetes Mellitus Treated Via the Basal-Bolus Detemir-Aspart Insulin Regimen: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Europeen d'Etude du Diabete</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Europeen d'Etude du Diabete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of the basal-bolus detemir-aspart insulin
      regimen coupled with continuous glucose monitoring (CGM) on glycemic control in hemodialyzed
      patients with diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We conducted a pilot prospective multicenter study in five French centers (Strasbourg
      University Hospital, Strasbourg Sainte Anne Hospital, Colmar, Mulhouse, Valenciennes)
      designed to evaluate the feasibility and effects of a 3 month treatment regimen with
      rapid-acting insulin and basal long-acting insulin analogues (i.e., aspart and detemir,
      respectively) along with CGM on glucose level control in diabetic hemodialyzed patients.

      All patients who were admitted to the nephrology departments and matched the inclusion
      criteria between January 1st, 2010, and June 30th, 2012, were consecutively included in the
      study. CGM was used to analyze blood glucose excursions at baseline and 1 and 3 months of
      treatment. It was started during the first dialysis session and then continued for the next
      two days at home under ambulatory conditions. The CGM was continued during the next dialysis
      session. Therefore, in total, CGM (Navigator®; Abbott, Rungis, France) was performed for 54
      hours, including two consecutive hemodialysis sessions and at 0, 1, and 3 months of
      treatment. The probe for the system was subcutaneously inserted at the beginning of the first
      dialysis session to analyze interstitial glucose, and it was removed at the end of the second
      dialysis session. Due to the time required for CGM calibration, plasma glucose levels were
      only partially recorded during the first dialysis session.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean plasma glucose level measured 3 times just before the first hemodialysis session</measure>
    <time_frame>Baseline and at 3 months of treatment</time_frame>
    <description>Determination by the glucose dehydrogenase method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline and at 3 months of treatment</time_frame>
    <description>Measured by high-performance liquid chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline and at 1 month and 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirements</measure>
    <time_frame>Baseline and at 1 month and 3 months of treatment</time_frame>
    <description>IU per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hypoglycemia</measure>
    <time_frame>Baseline and at 1 month and 3 months of treatment</time_frame>
    <description>Number of glycemia &lt; 60 mg/dl per patient and per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous glucose monitoring parameters</measure>
    <time_frame>Baseline and at 1 month and 3 months of treatment</time_frame>
    <description>Including: mean continuous glucose monitoring glucose values, within-subjects standard deviation (wSD) and coefficient of variation (wCV = wSD/mean), mean amplitude of glycemic excursion (MAGE), frequency of glucose values under 60 mg/dl, and frequency of glucose values higher than 180 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths and major cardiovascular events</measure>
    <time_frame>Baseline and at 3 months of treatment</time_frame>
    <description>All-cause mortality Major cardiovascular events including: myocardial infarction, stroke, and peripheral vascular disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Basal-bolus specific insulin regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal-bolus detemir-aspart insulin regimen</intervention_name>
    <description>After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.</description>
    <arm_group_label>Basal-bolus specific insulin regimen</arm_group_label>
    <other_name>Levemir</other_name>
    <other_name>Novorapid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 83 years

          -  diagnosis of type 1 or type 2 diabetes

          -  treatment with insulin injections or oral hypoglycemic agents

          -  HbA1c ≥ 7% (i.e., 53 mmol/mol)

          -  on hemodialysis for more than three months

        Exclusion Criteria:

          -  unstable anemia or blood transfusions within the two months prior to the beginning of
             the study

          -  a life expectancy of less than 1 year

          -  chronic inflammatory disease

          -  evolutive cancer requiring steroid treatment, chemotherapy, radiotherapy, or
             programmed surgery

          -  noncompliant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>83 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Kessler, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Hospital of Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte Anne Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>U S Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012. Available from http://www.usrds.org/atlas.aspx</citation>
  </reference>
  <reference>
    <citation>Heras M, Fernández-Reyes MJ, Sánchez R, Guerrero MT, Molina A, Rodríguez MA, Alvarez-Ude F. Elderly patients with chronic kidney disease: outcomes after 5 years of follow-up. Nefrologia. 2012 May 14;32(3):300-5. doi: 10.3265/Nefrologia.pre2012.Jan.10994. Epub 2012 Feb 28. English, Spanish.</citation>
    <PMID>22508140</PMID>
  </reference>
  <reference>
    <citation>Pieringer H, Biesenbach G. Hemodialysis in patients older than 65 years with end-stage renal failure--comparison of outcome in patients with and without diabetes. Z Gerontol Geriatr. 2008 Apr;41(2):139-45. doi: 10.1007/s00391-007-0467-x. Epub 2008 Mar 11.</citation>
    <PMID>18327697</PMID>
  </reference>
  <reference>
    <citation>Sattar A, Argyropoulos C, Weissfeld L, Younas N, Fried L, Kellum JA, Unruh M. All-cause and cause-specific mortality associated with diabetes in prevalent hemodialysis patients. BMC Nephrol. 2012 Oct 1;13:130. doi: 10.1186/1471-2369-13-130.</citation>
    <PMID>23025844</PMID>
  </reference>
  <reference>
    <citation>Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, Shoji T, Nishizawa Y. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care. 2006 Jul;29(7):1496-500.</citation>
    <PMID>16801568</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602.</citation>
    <PMID>9742976</PMID>
  </reference>
  <reference>
    <citation>McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis. 2002 Sep;40(3):566-75.</citation>
    <PMID>12200809</PMID>
  </reference>
  <reference>
    <citation>Okada T, Nakao T, Matsumoto H, Shino T, Nagaoka Y, Tomaru R, Wada T. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med. 2007;46(12):807-14. Epub 2007 Jun 15.</citation>
    <PMID>17575371</PMID>
  </reference>
  <reference>
    <citation>Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.</citation>
    <PMID>18539917</PMID>
  </reference>
  <reference>
    <citation>ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.</citation>
    <PMID>20228401</PMID>
  </reference>
  <reference>
    <citation>Riveline JP, Teynie J, Belmouaz S, Franc S, Dardari D, Bauwens M, Caudwell V, Ragot S, Bridoux F, Charpentier G, Marechaud R, Hadjadj S. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant. 2009 Sep;24(9):2866-71. doi: 10.1093/ndt/gfp181. Epub 2009 Apr 23.</citation>
    <PMID>19389864</PMID>
  </reference>
  <reference>
    <citation>Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FW, Dornhorst A, Frost G, Turner JJ. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009 Jul;32(7):1137-42. doi: 10.2337/dc08-1688. Epub 2009 Feb 5.</citation>
    <PMID>19196889</PMID>
  </reference>
  <reference>
    <citation>Vos FE, Schollum JB, Coulter CV, Manning PJ, Duffull SB, Walker RJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton). 2012 Feb;17(2):182-8. doi: 10.1111/j.1440-1797.2011.01517.x.</citation>
    <PMID>21883672</PMID>
  </reference>
  <reference>
    <citation>Ersoy A, Ersoy C, Altinay T. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus. Nephrol Dial Transplant. 2006 Feb;21(2):553-4. Epub 2005 Oct 12.</citation>
    <PMID>16221693</PMID>
  </reference>
  <reference>
    <citation>Schmitz O, Alberti KG, Orskov H. Insulin resistance in uraemic insulin-dependent diabetics. Effect of dialysis therapy as assessed by the artificial endocrine pancreas. Acta Endocrinol (Copenh). 1984 Mar;105(3):371-8.</citation>
    <PMID>6367331</PMID>
  </reference>
  <reference>
    <citation>Simic-Ogrizovic S, Backus G, Mayer A, Vienken J, Djukanovic L, Kleophas W. The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients. Int J Artif Organs. 2001 Dec;24(12):863-9.</citation>
    <PMID>11831591</PMID>
  </reference>
  <reference>
    <citation>Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med. 2003 Aug;20(8):642-5.</citation>
    <PMID>12873291</PMID>
  </reference>
  <reference>
    <citation>Cano N. Bench-to-bedside review: glucose production from the kidney. Crit Care. 2002 Aug;6(4):317-21. Epub 2002 Jun 7. Review.</citation>
    <PMID>12225606</PMID>
  </reference>
  <reference>
    <citation>Cersosimo E, Garlick P, Ferretti J. Renal substrate metabolism and gluconeogenesis during hypoglycemia in humans. Diabetes. 2000 Jul;49(7):1186-93.</citation>
    <PMID>10909977</PMID>
  </reference>
  <reference>
    <citation>Abe M, Kaizu K, Matsumoto K. Evaluation of the hemodialysis-induced changes in plasma glucose and insulin concentrations in diabetic patients: comparison between the hemodialysis and non-hemodialysis days. Ther Apher Dial. 2007 Aug;11(4):288-95.</citation>
    <PMID>17661835</PMID>
  </reference>
  <reference>
    <citation>Chujo K, Shima K, Tada H, Oohashi T, Minakuchi J, Kawashima S. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest. 2006 Aug;53(3-4):223-8.</citation>
    <PMID>16953058</PMID>
  </reference>
  <reference>
    <citation>Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005 Nov;60(5):469-76.</citation>
    <PMID>16236036</PMID>
  </reference>
  <reference>
    <citation>Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001 May;24(5):886-90.</citation>
    <PMID>11347749</PMID>
  </reference>
  <reference>
    <citation>Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med. 2011;4:827-35. doi: 10.2147/IJGM.S26889. Epub 2011 Dec 12.</citation>
    <PMID>22267935</PMID>
  </reference>
  <reference>
    <citation>Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007 May;9(3):418-27.</citation>
    <PMID>17391170</PMID>
  </reference>
  <reference>
    <citation>Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int. 2003 Oct;64(4):1480-6.</citation>
    <PMID>12969169</PMID>
  </reference>
  <reference>
    <citation>Tzamaloukas AH, Yuan ZY, Murata GH, Balaskas E, Avasthi PS, Oreopoulos DG. Clinical associations of glycemic control in diabetics on CAPD. Adv Perit Dial. 1993;9:291-4.</citation>
    <PMID>8105946</PMID>
  </reference>
  <results_reference>
    <citation>Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M; Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011 Nov 28;171(21):1920-7. doi: 10.1001/archinternmed.2011.537.</citation>
    <PMID>22123800</PMID>
  </results_reference>
  <results_reference>
    <citation>Hendriksen KV, Jensen T, Oturai P, Feldt-Rasmussen B. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients. Diabetologia. 2012 Jan;55(1):46-50. doi: 10.1007/s00125-011-2345-8. Epub 2011 Oct 16.</citation>
    <PMID>22002075</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Continuous glucose monitoring</keyword>
  <keyword>Insulin analogues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

